Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 17/20 | 0.59 |
| ▸ | CTSL | P07711 | 8/20 | 0.59 |
| ▸ | CTSB | P07858 | 5/20 | 0.59 |
| ▸ | CTSK | P43235 | 2/20 | 0.51 |
| ▸ | REN | P00797 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2163200 | 0.92 | CTSS (0.56) | CTSSCTSLCTSBCTSKREN | |
| SCHEMBL2164601 | 0.89 | CTSS (0.61) | CTSSCTSLCTSBCTSK | |
| SCHEMBL2163179 | 0.87 | CTSS (0.67) | CTSSCTSLCTSBCTSK | |
| SCHEMBL2163198 | 0.84 | CTSS (0.61) | CTSSCTSLCTSBCTSKREN | |
| SCHEMBL2164597 | 0.78 | CTSS (0.69) | CTSSCTSLCTSBCTSK | |
| SCHEMBL2163906 | 0.78 | CTSS (0.52) | CTSSCTSLCTSBCTSK | |
| SCHEMBL2163907 | 0.78 | CTSS (0.52) | CTSSCTSLCTSBCTSK | |
| SCHEMBL2163184 | 0.77 | CTSS (0.72) | CTSSCTSLCTSBCTSK | |
| SCHEMBL12196300 | 0.77 | CTSS (0.72) | CTSSCTSLCTSBCTSK | |
| SCHEMBL3957093 | 0.77 | CTSS (0.51) | CTSSCTSLCTSBCTSKREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1744755-B1 | COMPOUNDS AND COMPOSITIONS AS CATHEPSIN S INHIBITORS | IRM LLC (BM) | 2012-12-05 | — | — | EP | claimed |
| US-8268996-B2 | Compounds and compositions as cathepsin S inhibitors | IRM LLC (BM) | 2012-09-18 | — | — | US | claimed |
| US-20110245243-A1 | COMPOUNDS AND COMPOSITIONS AS CATHEPSIN S INHIBITORS | NOVARTIS AG | 2011-10-06 | — | — | US | claimed |
| US-20070232606-A1 | Compounds and Compositions as Cathepsin S Inhibitors | IRM LLC (BM) | 2007-10-04 | — | — | US | claimed |
| EP-1744755-B1 | COMPOUNDS AND COMPOSITIONS AS CATHEPSIN S INHIBITORS | IRM LLC (BM) | 2012-12-05 | — | — | EP | disclosed |
| US-8268996-B2 | Compounds and compositions as cathepsin S inhibitors | IRM LLC (BM) | 2012-09-18 | — | — | US | disclosed |
| US-20110245243-A1 | COMPOUNDS AND COMPOSITIONS AS CATHEPSIN S INHIBITORS | NOVARTIS AG | 2011-10-06 | — | — | US | disclosed |
| US-7985749-B2 | Compounds and compositions as cathepsin S inhibitors | NOVARTIS AG (CH) | 2011-07-26 | — | — | US | disclosed |
| US-20070232606-A1 | Compounds and Compositions as Cathepsin S Inhibitors | IRM LLC (BM) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232606-A1 | Compounds and Compositions as Cathepsin S Inhibitors | CTSS, CTSB, CTSF | CTSS 1/4885CTSL 11/4885CTSB 2/4885 |
| US-20110245243-A1 | COMPOUNDS AND COMPOSITIONS AS CATHEPSIN S INHIBITORS | CTSS, CTSB, CTSF | CTSS 1/4885CTSL 11/4885CTSB 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.